Health & Biotech
ASX Quarterly Health Wrap: Imricor starts CY25 strong, Clever Culture eyes FY25 profit
Health Check: Snore-buster Resmed says miracle diet drugs and tariffs no threat to growth
Dr Boreham’s Crucible: WISE guys de-risked with FDA approval for EBR cardiac device
Medicare coverage advances for Lumos’ FebriDx point-of-care respiratory test
Island phase 2a/b mosquito-borne dengue fever results due in May
Health Check: Telix shares rocket after bullish quarterly sales update
Biocurious: In a torrid capital raising climate, early-stage biotechs turn to alternative funding
Big pharma Sandoz steps into Aussie CBD scene; could this be the start of a rush?
Recce to expand Phase II trial for diabetic foot infections
Health Check: In rude health, Alcidion shrugs off UK National Health Service reforms
East Meets West: AdAlta navigates China–US divide to drive biotech value
Lumos soars on US wins for FebriDx point-of-care respiratory test
Imricor wins European assent for its world-leading heart tool
Neurizon strengthens leadership on path to commercialisation
Health Check: Aussie biotechs avoid DEFCON-1 alert amid tariff war – but it’s no time to be off guard
Road to 2025: Clever Culture Systems advancing APAS Independence
Arovella tackles CAR-T’s limitations in cancer treatment with off-the-shelf innovation
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
